np event 2254995 0E193A 1
Oct 8, 2026
- Oct 7, 2027

Beyond Symptom Control: Targeting BAFF/APRIL Pathways in Generalized Myasthenia Gravis

EARNed Credits

1.0

AMA PRA Category 1 CreditTM

Vor Bio AANEM Image

Overview

This CME activity is derived from content presented at the 2026 AANEM Annual Meeting in Orlando, Florida. The expert faculty, Drs. Katherine Ruzhansky, Ali Habib and Gil I. Wolfe, will begin the lecture with an update on the disease-modifying treatment for patients with generalized myasthenia gravis (gMG). Following, current clinical trial data regarding fusion protein dual BAFF and APRIL cytokine inhibitors will be reviewed, including an analysis of the clinical relevance of these therapeutic agents for the busy clinician. The faculty will conclude with best practices for individualizing treatment plans for patients with gMG, to improve patient outcomes, symptom burden and quality of life.

Who Should Attend

Neuromuscular disease specialists, general neurologists, their expanded care teams, and other healthcare providers who contribute to the management of patients with gMG.

Provided By

Course Faculty

HABIB
Ali A. Habib, MD
Associate Professor, Department of Neurology
UC Irvine School of Medicine
Orange, CA
Katherine Ruzhansky, MD, MS
Katherine Ruzhansky, MD, MS
Professor of Neurology
Director of the Neuromuscular Division and EMG Lab
Medical University of South Carolina
Charleston, SC
Gil I. Wolfe, MD, FAAN
Gil I. Wolfe, MD
SUNY Distinguished Professor
Department of Neurology/UBMD Neurology
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo/SUNY
Buffalo, NY

Learning Objectives

1

Review the current therapeutic landscape for the disease-modifying treatment of patients with gMG and identify unmet patient needs

2

Discuss the mode of action and current clinical trial data for dual fusion protein treatments for patients with gMG

3

Develop strategies for developing individualized treatment plans to manage patients with AChR-Ab or MuSK-Ab positive gMG, including the potential role of BAFF/APRIL inhibitors

Course Agenda

I. Welcome & Introductions

II. Update on the Disease-Modifying Treatment of Patients with Generalized Myasthenia Gravis

III. Fusion Protein Dual BAFF and APRIL Cytokine Inhibitors

IV. Strategic Considerations for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis

V. Faculty Panel Discussion

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty Relationship Identified With:
Katherine Ruzhansky, MD (Chair)

 

Consultant Advisor: Amgen; Kyverna Therapeutics, Inc; UCB S.A, Belgium

Grant/Research Support: COUR Pharmaceuticals; Immunovant, Inc.; Janssen Pharmaceuticals, Inc.; Paradromics

Ali A. Habib, MD

 

Consultant Advisor: Alexion Pharmaceuticals, Inc.; Amgen; argenx; AstraZeneca; Bristol-Myers Squibb Company; Cabaletta Bio, Inc.; Cartesian Therapeutics, Inc.; Gilead Sciences, Inc; Grifols, S.A; Janssen Pharmaceuticals, Inc.; Kyverna Therapeutics, Inc; Merck & Co., Inc.; NMD Pharma; Novartis Pharmaceuticals Corporation; Regeneron; UCB S.A, Belgium; Vor Biopharma

Grant/Research Support: argenx; Bristol-Myers Squibb Company; Cabaletta Bio, Inc.; Gilead Sciences, Inc; Kyverna Therapeutics, Inc; Merck & Co., Inc.; Nkarta, Inc.; NMD Pharma; Novartis Pharmaceuticals Corporation; Regeneron; Vertex Pharmaceuticals Incorporated; Vor Biopharma

Speaker’s Bureau: Alexion Pharmaceuticals, Inc.; Amgen; argenx; AstraZeneca; Grifols, S.A; Janssen Pharmaceuticals, Inc.; UCB S.A, Belgium

Gil I. Wolfe, MD

 

Consultant Advisor: Alexion Pharmaceuticals, Inc.; argenx; BPL; Cartesian Therapeutics, Inc.; Canopy Life Sciences; Dianthus Therapeutics; Grifols, S.A; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; UCB S.A, Belgium

Grant/Research Support: Alexion Pharmaceuticals, Inc.; argenx; Immunovant, Inc.; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals; UCB S.A, Belgium

Speaker’s Bureau: Grifols, S.A; Janssen Pharmaceuticals, Inc.; UCB S.A, Belgium

Timothy Hayes, MD, PhD; Kim Cheramie, PhD, MSN, RN, NPDA-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Vor Biopharma.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Vor Biopharma do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the Pre-Activity Questions
    3. Read or Review the activity content.
    4. Complete the Post-Activity Test Questions and Evaluation.
    5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact admin@academiccme.com.

np event 2254995 0E193A 1
Oct 8, 2026
- Oct 7, 2027

Beyond Symptom Control: Targeting BAFF/APRIL Pathways in Generalized Myasthenia Gravis

Related Webcast Courses

np document 888746 0E193A 5
Neurology
The New Era of B and T Cell, Co-Stimulatory, CD40/CD40L Therapeutics to Target Neuroinflam...
np document 888746 0E193A 5
Neurology
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Improving Function and Reducing ...
np document 888746 0E193A 5
Neurology
Clinical Update on the Evolving Role of B-Cell Targeting Therapies to Improve Outcomes in ...